The CD70-targeting CTX131 heads for the scrapheap.
ApexOnco Front Page
Recent articles
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
The ROR1 data are sketchy, and lung toxicity clouds prospects.
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.
Meanwhile, Bristol’s other competition in this disease looks set to come from China.